GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Protext Mobility TXTM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.01

+0.66%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Protext Mobility

Its shares trade under the ticker TXTM. It has been listed since 21 August 2003.

ProText Mobility, Inc. engages in the development of pharmaceutical applications for botanical drugs. The company is headquartered in Miami, Florida. The company went IPO on 2003-08-21. The firm is engaged in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology. The Company’s subsidiaries include Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
21 Aug 2003

Leadership

Pay as last reported

  • Mr. Roger Baylis-DuffieldChief Executive Officer, Director, since 2016
  • Mr. David LewisDirector, since 2009$180,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Protext Mobility Inc develops pharmaceutical applications for botanical drugs in the US market.
  • The firm uses proprietary live plant extraction technology for highly bioavailable products.
  • Subsidiaries include Plandai Biotechnology South Africa and Cannabis Biosciences, Inc for global reach.

Weaknesses

  • The company is headquartered in Miami, Florida, which may limit local talent pools.
  • Listing occurred on 21 August 2003, indicating a long public market history.
  • Reliance on all-natural ingredients may constrain production scalability compared to synthetic alternatives.

Opportunities

  • Expansion into the South African market through Plandai Biotechnology South Africa offers growth.
  • Development of nutraceutical applications can diversify revenue streams beyond pharmaceuticals significantly.
  • Increasing demand for botanical drugs creates new opportunities for proprietary technology licensing.

Threats

  • Regulatory changes in the US could impact the approval of botanical drugs.
  • Competition from synthetic pharmaceuticals may reduce market share for natural ingredient products.
  • Economic instability in South Africa poses risks to the Plandai subsidiary operations.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.